The number of high-stakes securities class action filings has grown dramatically in recent years, with a steady increase in cases against life science companies and a recent surge in merger objection cases. This dynamic area of the law requires a deep bench of experience as well as a nimble legal team that can keep pace with evolving law and rapidly changing trends.
We represent plaintiffs and corporate defendants as well as individual officers and directors across a broad spectrum of high-impact cases. Our team defends securities class actions, shareholder derivative litigation, and ERISA litigation, and advises companies large and small on how best to navigate sensitive internal and governmental investigations. We are among the handful of firms with lawyers who have tried a securities class action to a jury verdict.
Because we have worked securities litigation matters from every angle, our creative strategies cut the shortest path to a favorable resolution. Our reputation for innovation is why clients reach out to us to help resolve longstanding cases.
Whether advising a Silicon Valley startup or representing a century-old Fortune 500 firm in multijurisdictional parallel actions, we deliver outstanding results across a range of industries, markets, and businesses.
Willa Rosenbloom v. Pyott (Allergan). Obtained dismissal with prejudice of multiple shareholder derivative actions asserting that Allergan’s board members failed to prevent alleged off-label marketing violations.
In re Amgen Inc. Securities Litigation. Representing Amgen, the world’s largest biopharmaceutical company, in a multibillion-dollar national securities fraud class action alleging misstatements and omissions related to several of Amgen’s most important drugs. Amgen retained us after the case was remanded by the Supreme Court of the United States. In related litigation, we successfully moved to dismiss multiple shareholder derivative actions in state and federal courts and favorably settled other actions to finally resolve the decade-old case.
Pacific Select Fund v. Bank of New York Mellon et al. Obtained $20 million for Pacific Life against Bank of New York Mellon at the summary judgment stage in a breach of contract and breach of fiduciary duty matter in investment mismanagement litigation. Later secured an additional $30 million settlement on the eve of trial.
Secured termination of SEC investigation of high-level PIMCO officer relating to allegations of misleading investors about the performance of a fund and alleged failure to accurately value certain fund securities.
State Compensation Insurance Fund v. Fuld et al. Represented the State Fund against former Lehman Brothers executives in a securities fraud lawsuit designed to recoup the value of investment bonds the State Fund purchased from 2005 through 2008. We defeated motions to dismiss and were able to secure an early settlement at the conclusion of fact discovery.
Securities and Exchange Commission v. Movie Studio Executive. Represented a corporate officer in the motion picture industry in an SEC investigation and litigation concerning insider trading.
Represented one of the largest providers of interactive media services to the hospitality and health care industries in the successful defense of an action brought to enjoin a critical debt transaction, obtaining a complete dismissal.